3,279,401 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by RA Capital Management L.P.

RA Capital Management L.P. acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 3,279,401 shares of the company's stock, valued at approximately $47,092,000. RA Capital Management L.P. owned about 2.71% of 10x Genomics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock worth $8,027,000 after purchasing an additional 277,355 shares during the period. Entropy Technologies LP lifted its position in shares of 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock worth $540,000 after purchasing an additional 27,844 shares during the period. SG Americas Securities LLC raised its holdings in 10x Genomics by 209.8% in the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock worth $1,049,000 after purchasing an additional 49,468 shares in the last quarter. Alberta Investment Management Corp purchased a new position in shares of 10x Genomics during the fourth quarter valued at approximately $3,206,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in 10x Genomics in the fourth quarter worth $326,000. Institutional investors and hedge funds own 84.68% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Barclays lowered their price target on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and cut their price target for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price objective on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. Finally, Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $18.85.

10x Genomics Trading Up 2.1 %

Shares of NASDAQ:TXG traded up $0.18 during mid-day trading on Monday, reaching $8.61. The stock had a trading volume of 3,364,290 shares, compared to its average volume of 2,265,828. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $28.25. The firm has a 50 day simple moving average of $9.17 and a two-hundred day simple moving average of $12.78. The firm has a market cap of $1.05 billion, a PE ratio of -5.66 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan Mateo acquired 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the purchase, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. The trade was a 184.41 % increase in their position. The disclosure for this purchase can be found here. 10.03% of the stock is owned by insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.